This is the authors' abstract. We don't add key points for this paper.
Plasma levels of IGF-I are higher and plasma levels of IGFBP-3 are lower in patients with lung cancer than in control subjects. If these findings can be confirmed in prospective studies, measuring levels of IGF-I and IGFBP-3 in blood may prove useful in assessing lung cancer risk.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yu et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: